product name Embelin
References: [1] Nikolovska-Coleska Z, et al. J Med Chem, 2004, 47(10), 2430-2440.; [2] Schaible AM, et al. Biochem Pharmacol, 2013, 86(4), 476-486.
294.39
Formula
C17H26O4
CAS No.
550-24-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 59 mg/mL (200.41 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: 12 mg/mL (40.76 mM)
Solubility (In vivo)
Chemical Name
2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione
other peoduct :
| Embelin from the Japanese Ardisia herb is a small-molecular inhibitor that binds to the XIAP BIR3 domain with which Smac and caspsase-9 bind. Embelin inhibits cell growth of both PC-3 and LNCap cells in a dose-dependent manner, with IC50 values of 3.7 and 5.7 μM. While, the toxicity of Embelin in normal PrEC and in WI-38 cells is much lower with IC50 values of 20.1 μM and 19.3 μM. | |
|---|---|
| In Vivo | Embelin has also been used extensively in various animal models to study the role of XIAP. In the azoxymethane/dextran sulfate sodium (AOM/DSS) induced colitis-associated cancer (CAC) model, embelin reduced both incidence and tumor size in mice by inhibiting proliferation of tumor epithelial cells and suppressing IL6 expression and IL6-activated STAT3 in vivo. |
| Animal model | AOM/DSS-induced colitis-associated cancer (CAC) model |
| Formulation & Dosage | 50 mg/kg/day; p.o. |
| References | Mol Cancer Ther 2014,13:1206-1216. |
